PPAR Research

PPAR Research is a peer-reviewed open access journal devoted to the biology of the peroxisome proliferator-activated receptors, founded in 2005 and published by Wiley since 2023.《PPAR 研究》是一份同行评审的开放获取期刊，专注于过氧化物酶体增殖物激活受体的生物学，创办于 2005 年，自 2023 年起由 Wiley 出版。

The title carries original research and review articles on the mechanisms by which these nuclear receptors are switched on and on the part they play in metabolism and disease.该刊刊载原创研究与综述文章，内容涉及这类核受体的激活机制，以及它们在代谢与疾病中扮演的角色。

In the 2025 edition of the journal citation report the title holds an impact factor of 3.3 and stands in the second quartile of medicine, research and experimental.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在医学研究与实验类目中列第二区。

Scope

• The journal takes work on the mechanisms that govern the activation of the peroxisome proliferator-activated receptors, which act as ligand activated transcription factors.该刊收载过氧化物酶体增殖物激活受体激活机制的工作，这类受体充当配体激活的转录因子。

• Three subtypes are recognised, and studies of alpha, beta or delta and gamma, together with their isoforms, all fall inside the remit.已知的亚型共三种，针对 α、β 或 δ 以及 γ 及其异构体的研究都在收稿范围之内。

• The role of the receptors in the regulation of cellular differentiation is treated as a central theme of the journal.这类受体在细胞分化调控中的作用被视为该刊的中心主题。

• Development is covered alongside differentiation, with work on the way the receptors shape the growth of tissues and organs.发育与分化并列得到覆盖，受体如何塑造组织与器官生长的工作也在其中。

• Energy homeostasis forms another named area, and the journal carries material on the balance between energy intake and expenditure.能量稳态构成又一个点名领域，该刊刊载能量摄入与消耗之间平衡方面的材料。

• The metabolic function of the receptors, and the way it is disturbed in chronic disease, is written into the subject.受体的代谢功能，以及这一功能在慢性病中被打乱的方式，都写入了选题范围。

• Pre-clinical trials of drugs that modulate the activity of the receptors are welcomed, and the same is true of clinical trials in patients.能够调节受体活性的药物的前临床试验受到欢迎，患者身上的临床试验同样如此。

• Dyslipidaemia is named among the conditions the journal addresses, and so is adipocyte differentiation.血脂异常被点名列为该刊关注的情形之一，脂肪细胞分化也在其列。

• Diabetes belongs to the same list, and the journal takes both the experimental and the clinical side of glucose and lipid disorders.糖尿病属于同一份名单，该刊对糖脂紊乱的实验层面与临床层面都予收载。

• Inflammation and cancer are covered, and the receptors are considered in the light of their contribution to tumour biology and to the inflammatory response.炎症与癌症得到覆盖，受体在肿瘤生物学与炎症反应中的贡献也在考察之列。

• Lung diseases and neurodegenerative disorders appear in the statement of aims, together with obesity and the metabolic consequences that follow from it.肺部疾病与神经退行性疾病见于宗旨说明，肥胖以及随之而来的代谢后果也在其中。

• Review articles are taken alongside the primary reports, and the journal checks every submission for overlap before it enters review.综述文章与原始报告一并收载，来稿在进入评审之前会先做重复度检查。

• The journal takes work on the ligands that switch the receptors on, and on the synthetic compounds designed to act at those sites.该刊收载开启受体的配体，以及为作用于这些位点而设计的合成化合物的研究。

• Interactions between the receptors and other nuclear receptors, notably the retinoid X receptors, come within the remit.这些受体与其他核受体之间的相互作用，尤其是与类视黄醇 X 受体的作用，属于收稿范围。

• Studies of the part the receptors play in the vasculature and in cardiac muscle are admitted.受体在血管与心肌中所起作用的研究也在接纳之列。

• The journal also prints work on the pharmacology of the agonists and antagonists that act on the receptors and on the safety questions these agents raise.该刊还刊载作用于受体的激动剂与拮抗剂的药理学研究，以及这些药物所引发的安全性问题。

History

• The journal was begun in 2005 by Mostafa Z. Badr of the University of Missouri-Kansas City, and the first volume was gathered under the year 2006.该刊由密苏里大学堪萨斯城分校的（Mostafa Z. Badr）于 2005 年发起创办，第 1 卷以 2006 年为卷年成册。

• The founding publisher was Hindawi Publishing Corporation, and early articles carry the identifier prefix 10.1155.创始出版方是 Hindawi Publishing Corporation，早期论文带有 10.1155 这一标识符前缀。

• At the outset the journal issued several themed issues a year, and the volumes of the first decade were put together from special issues guest edited by outside scholars.创办之初该刊每年推出数个专题期，头十年的各卷由外部学者客座主编的专刊汇成。

• From 2023 the title has been issued by Wiley, and the catalogue of the national medical library names a current imprint in Hoboken, New Jersey.自 2023 年起该刊由 Wiley 出版，美国国立医学图书馆的目录把现行出版信息记在新泽西州霍博肯。

• The journal numbers a volume by the calendar year rather than by a run of issues, so that the volume for 2026 is simply called 2026.该刊按日历年份而非期号序列编卷，因而 2026 年的那一卷就直接称作 2026。

• The print number is 1687-4757 and the electronic number is 1687-4765, and the abbreviation used in the indexes is PPAR Res.印刷版编号为 1687-4757，电子版编号为 1687-4765，索引中使用的缩写是 PPAR Res。

• PubMed has carried the title from 2006, and the full text is also deposited in PubMed Central.PubMed 自 2006 年起收录该刊，全文也存入 PubMed Central。

• The impact indicator has moved from 4.964 and 4.385 to 3.5 and 3.1, and it stood at 3.3 in the 2025 edition.影响因子从 4.964 与 4.385 变为 3.5 与 3.1，在 2025 年版为 3.3。

• The journal became open access at its foundation and has remained so, and every article is free to read from the moment it is published.该刊自创办起即为开放获取并保持至今，每篇文章自发表那一刻起便可免费阅读。

• Digital preservation is provided by Portico and by the LOCKSS programme, so that the record survives independently of any one publisher.数字保存由 Portico 与 LOCKSS 计划提供，使刊物记录得以独立于任何单一出版方而存续。

Editors

• The founding editor-in-chief was Mostafa Z. Badr, then at the University of Missouri-Kansas City in the United States, who led the journal from 2005 until 2011.创始主编是当时在密苏里大学堪萨斯城分校的（Mostafa Z. Badr），主持该刊自 2005 年直至 2011 年。

• In the founding years an advisory board sat with the editor, and its members came from North America, Europe and Asia.创办初期有一支顾问编委会与主编共事，成员来自北美、欧洲与亚洲。

• That early board included Yaacov Barak, Michael K. Racke, Janardan K. Reddy and Beata Lecka-Czernik of the United States, Francine M. Gregoire of Singapore, Sander Kersten of the Netherlands, Abdulbari B. Bener of Qatar, David Bishop-Bailey of the United Kingdom and Bart Staels of France.那支早期编委会包括美国的（Yaacov Barak）、（Michael K. Racke）、（Janardan K. Reddy）与（Beata Lecka-Czernik），新加坡的（Francine M. Gregoire），荷兰的（Sander Kersten），卡塔尔的（Abdulbari B. Bener），英国的（David Bishop-Bailey）与法国的（Bart Staels）。

• The title runs anonymous peer review, so the identity of a referee is withheld from the author of the paper.该刊实行匿名同行评审，审稿人的身份对论文作者保密。

• Submission to publication is estimated at about twelve weeks, and the journal checks submissions for plagiarism as part of its process.自投稿到发表估计约十二周，该刊在流程中会对来稿做抄袭检查。

• An article processing charge is levied on accepted papers, set at 1790 United States dollars or the equivalent in sterling or euros, and a waiver policy exists for authors who cannot pay.被录用的论文须缴纳文章处理费，标准为一千七百九十美元或等值的英镑与欧元，对无力支付的作者另设减免政策。

• Articles are published under a Creative Commons attribution licence, and the author keeps the copyright of the work.文章以 Creative Commons 署名许可发布，著作权仍归作者所有。

• Guest editors have led many of the special issues, and topics such as the molecular basis of receptor function and the interaction of the receptors with drug metabolising enzymes have been gathered this way.许多专刊由客座编辑主持，受体功能的分子基础，以及受体与药物代谢酶相互作用等题目都以此方式成辑。

• The editorial office handles manuscripts through an online system, and the journal sets out its expectations for authors in a published set of guidelines.编辑部通过在线系统处理稿件，并以公开的投稿指南说明对作者的要求。

• The journal is indexed in the science citation services, in MEDLINE's sibling databases and in the Directory of Open Access Journals, which records its two numbers and its licence terms.该刊被科学引文服务、医学文献数据库以及开放获取期刊目录收录，后者记录了它的两个刊号与许可条款。